Božena Nováková, Ján Fedačko
Non-alcoholic fatty liver - NAFLD (Non-Alcoholic Fatty Liver Disease) is currently the world’s most common liver disease. In developed western countries it reaches the nature of the epidemy. The incidence of steatosis in normal adult population is estimated to 20-30 % in the population of obese and in diabetic patients the incidence of NAFLD increases to 70-90 %. NAFLD represents a spectrum from simple hepatic steatosis through nonalcoholic steatohepatitis - NASH, to liver cirrhosis. Currently, we consider non-alcoholic fatty liver as a hepatic manifestation of NAFLD in metabolic syndrome and its component. The aim of this work is to refer the relationship of steatosis, dyslipidemia and increased cardiovascular risk in patients with metabolic syndrome.
Keywords: fatty liver, dyslipidemia, metabolic syndrome